# PolyPid

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/polypid

- Industry: Biotechnology
- Headquarters: Petah Tikva, Israel
- Website: www.polypid.com
- Total disclosed funding: $22M
- Latest round: Series D (Feb 24, 2016)
- Investors on record: 2

## About

Based in Petach Tikva, Israel, 2008, PolyPid Ltd., a.k.a. PolyPid operates as a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies to enhance surgical outcomes. In January 2024, PolyPid Ltd. raised USD 16.2 million in PIPE funding from DAFNA Capital Management and Rosalind Advisors.

PolyPid's product candidates are designed for extended, localized release of medications over days to months, targeting issues such as infection, pain, inflammation, and cancer. The company’s flagship products, D-PLEX100 and D-PLEX1000, are specifically developed to prevent surgical site infections and address bone-related infections using advanced, localized delivery mechanisms.

## Funding rounds

- Series D, Feb 24, 2016, $22M — Shavit Capital, Aurum Ventures

## Investors

- Shavit Capital (https://capitalatlas.ai/funds/shavit-capital) — Series D
- Aurum Ventures (https://capitalatlas.ai/funds/aurum-ventures) — Series D